Terumo's First-Half Revenue Rises 16.7%, Despite Asset Impairment
Terumo Corporation’s first-half revenue increased 16.7% year-over-year to ¥624.5 billion, but the company reported a significant asset impairment charge that overshadowed gains, revealing a complex picture of growth alongside emerging challenges. The revenue increase was primarily fueled by strong performance in overseas markets, particularly in interventional systems and the blood/cell technology business, alongside a favorable exchange rate.
Despite the top-line growth, Terumo recorded a substantial ¥70.1 billion impairment loss related to the termination of a supply agreement with CSL Plasma. This write-down, combined with a temporary supply constraint in the neuro business, led to a decrease in operating and net profits despite a 28.8% jump in adjusted operating profit. The impairment charge reflects a reassessment of future profitability tied to the lost contract, a strategic setback that directly impacted the bottom line. This echoes concerns flagged in late 2026, when Terumo first announced the potential impact of the CSL Plasma agreement termination, and a subsequent downward revision of its full-year profit forecast.
The company’s performance varied by segment. The cardiovascular company saw a 15.6% revenue increase, while the medical care solutions and blood/cell technology businesses grew by 9.5% and 16.5%, respectively. The recent acquisition of Arsenal Medical also contributed to results, adding ¥11.6 billion in revenue. However, the financial impact of the impairment obscured these positive trends, highlighting the vulnerability of Terumo’s profitability to disruptions in key partnerships.
Terumo’s cash flow from operations increased to ¥149.6 billion, but investment activity saw an outflow of ¥27.0 billion, reflecting investments in production facilities and IT systems. The company also executed a syndicated loan agreement for ¥1,192 billion and repaid ¥2,700 billion in long-term debt. While the company’s revenue is trending upward, the significant impairment charge and associated financial implications point to a more challenging path to sustained profitability. The results underscore the importance of diversifying revenue streams and mitigating risks associated with key supplier relationships.